Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710650 | 0.82 | PIM1 (0.43) | MAOBGSK3BMAOAALDH1A1MEN1 | |
| SCHEMBL26244629 | 0.79 | MAOB (0.52) | MAOBMAOAALDH1A1MEN1LMNA | |
| SCHEMBL26244655 | 0.78 | MAPT (0.53) | MAOBMAOAALDH1A1MEN1LMNA | |
| SCHEMBL16708233 | 0.73 | TAS1R3 (0.53) | MAOBGSK3BMAOAALDH1A1LMNA | |
| SCHEMBL16708142 | 0.72 | PIM1 (0.38) | GSK3BALDH1A1MEN1LMNAMAPT | |
| SCHEMBL16708178 | 0.72 | PIM1 (0.72) | MAOBALDH1A1MEN1LMNAMAPT | |
| SCHEMBL24791806 | 0.70 | MAOB (0.50) | MAOBMAOAALDH1A1F12GPR35 | |
| SCHEMBL16708124 | 0.70 | GSK3B (0.44) | MAOBGSK3BALDH1A1MEN1LMNA | |
| SCHEMBL5772244 | 0.70 | CA12 (0.38) | ALDH1A1LMNAMAPTHTTPIM1 | |
| SCHEMBL5771969 | 0.67 | LMNA (0.39) | MEN1LMNAMAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862730-B2 | Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | MAOB 2077/4885GSK3B 1150/4885MAOA 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.